Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline
| Autor: | Michael E. Ernst, Anne M. Murray, Suzanne G Orchard, Jessica E. Lockery, Mark Nelson, Rory Wolfe, John J McNeil, Stephanie A. Ward, Robyn L. Woods, Trevor T.-J. Chong, Joanne Ryan, Jeff D. Williamson, Brenda Kirpach, Elsdon Storey, Raj C. Shah, Anne B. Newman, Christopher M. Reid, Ruth E Trevaks |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Null Hypothesis Placebo-controlled study Verbal learning Placebo law.invention Double-Blind Method Randomized controlled trial law Internal medicine mental disorders medicine Humans Dementia Cognitive Dysfunction Prospective Studies Cognitive decline Aged Aged 80 and over Aspirin business.industry Dementia Vascular Anti-Inflammatory Agents Non-Steroidal medicine.disease Treatment Outcome Female Neurology (clinical) Alzheimer's disease business Follow-Up Studies medicine.drug |
| Zdroj: | Neurology |
| ISSN: | 1526-632X 0028-3878 0103-8583 |
| Popis: | ObjectiveTo determine the effect of low-dose aspirin vs placebo on incident all-cause dementia, incident Alzheimer disease (AD), mild cognitive impairment (MCI), and cognitive decline in older individuals.MethodsAspirin in Reducing Events in the Elderly (ASPREE) was a double-blind, placebo-controlled trial of low-dose aspirin. In the United States and Australia, community-dwelling individuals aged ≥70 years (US minorities ≥65 years) and free of cardiovascular disease, physical disability, and diagnosed dementia were enrolled. Participants were randomized 1:1–100 mg daily aspirin or placebo. The Modified Mini-Mental State Examination, Hopkins Verbal Learning Test–Revised, Symbol Digit Modalities Test, and Controlled Oral Word Association Test assessed cognition at baseline and over follow-up. Additional cognitive testing was performed in participants with suspected dementia (“trigger”) based on within-study assessments or clinical history. Dementia was adjudicated according to DSM-IV criteria. National Institute on Aging–Alzheimer’s Association criteria were used for AD and MCI subclassification.ResultsA total of 19,114 participants were followed over a median 4.7 years and 964 triggered further dementia assessments. There were 575 adjudicated dementia cases, and 41% were classified as clinically probable AD. There was no substantial difference in the risk of all dementia triggers (hazard ratio [HR], 1.03; 95% confidence interval [CI], 0.91–1.17), probable AD (HR, 0.96; 95% CI, 0.74–1.24), or MCI (HR, 1.12; 95% CI, 0.92–1.37) between aspirin and placebo. Cognitive change over time was similar in the aspirin and placebo groups.ConclusionsThere was no evidence that aspirin was effective in reducing risk of dementia, MCI, or cognitive decline. Follow-up of these outcomes after initial exposure is ongoing.Classification of evidenceThis study provides Class II evidence that for healthy older individuals, low-dose aspirin does not significantly reduce the incidence of dementia, probable AD, MCI, or cognitive decline.Clinicaltrials.gov identifierNCT01038583. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|